Discussion: (0 comments)
There are no comments available.
View related content: Constitution
Not so long ago, the Roberts Court drew a torrent of commentary–most of it
critical–about its supposed pro-business orientation. “Supreme Court, Inc.” was
the title of an article by law professor Jeffrey Rosen in the New York
Times Magazine. This year, with a heavily Democratic Congress
relieving its pent-up demand for regulation, as well as a financial disaster
supposedly caused by “deregulation” and a new administration with a declared
intention to reconstruct the American economy, many expected a confrontation
between populist politics and the Supreme Court’s insistence on a modicum of
government restraint and reason. But the justices’ recent decision in Wyeth
v. Levine suggests just the opposite. The Court’s doctrines on the
once-arcane subject of “federal preemption” extend an open invitation to juries,
state officials, and tort lawyers to help themselves to even more of the
diminishing proceeds of America’s productive economy.
Wyeth arose over a tragic injury to a patient whose doctor and
nurse, in an act of flagrant malpractice, had administered a drug in direct
contravention of the federally approved warning label. The wording of that label
conformed with–in fact, was practically dictated by–FDA requirements. This
should have sufficed to shield the drug company from liability in state courts
in cases of misuse; in legalese, the federal law–in this case, the Food, Drug
and Cosmetics Act (FDCA)–should “preempt” the imposition of state-law
liability. But by a 6-3 majority, the court decided against preemption. (Justice
Alito dissented, joined by Chief Justice Roberts and Justice Scalia.) The
adequacy of drug labels will henceforth be determined not by FDA experts but by
random juries with massive hindsight bias.
The effects of this ruling reach far beyond the pharmaceutical industry.
Federal preemption is the only available defense for virtually any industry
against rapacious tort lawyers and ambitious state attorneys general. Without
it, a manufacturer will potentially be subject to 50-odd different sets of rules
within the United States, all of them subject to change at the whim of juries
and judges. The risk of confusion and balkanization is compounded by a
relentless pro-regulatory bias: in integrated product markets, producers must of
necessity comply with the law of the most restrictive state.
Over the past decade, corporations and defense lawyers have refined and
coordinated their preemption arguments. Their main focus has been “implied”
preemption–the position that a federal statute can trump conflicting state law,
including state tort law, even if it does not expressly preempt it. The
central case for that proposition is, or was, Geier v. Honda Motor Co.
(2000), a case involving an accident in a car that was not equipped with
airbags. Justice Breyer’s opinion for the majority held that federal health and
safety statutes (in that case, the National Highway Traffic Safety Act), along
with agency regulations implementing them, preempt state law by implication when
the federal standards establish, not a minimum, but rather an optimum
standard. The reasoning was that because excessively strict standards can
increase risk just as unduly lax ones can (by discouraging or slowing
innovation, for example), jury-imposed liability standards beyond the federally
determined optimum conflict with federal law, and are therefore preempted. (In
Geier, federal regulators had chosen, for safety reasons, to phase in
airbags over a period of years, as opposed to mandating them immediately for the
entire new car fleet. The court held that states could not vitiate this policy
by means of tort standards.)
After Wyeth, however, Geier is a dead letter, at least with
respect to labeling and disclosure requirements. If any federal statute
constitutes an attempt to strike an optimum balance among risks, it is the FDCA.
Every medicine has side effects and can be misused, so what is the point of the
federal drug-approval process if not to balance these risks against the benefits
of a drug that would save lives? What is the point of labeling standards if not
to guard against the twin dangers of under- and over-warning? And what remains
of the FDA’s mission now that any jury can hold any pharmaceutical company
liable for any reason–or, so far as federal law is concerned, for no reason at
Far worse than Justice Stevens’s majority opinion is Justice Thomas’s
concurrence. Incredibly, it berates the majority for an undue solicitude of
preemption and makes it hard to conceive of any room at all for implied
That may sound reasonable: “If Congress wants to preempt, let it say so
clearly,” rings the refrain. Justice Thomas’s opinion is the most extreme
expression of that position to date. Yet its obtuseness borders on willful
denial. The states have every incentive and myriad ways to circumvent federal
law. Because Congress cannot possibly foresee those stratagems, it cannot
“clearly” preempt them. For example, the clearest federal preemption provision
of all prohibits states from administering “a law or regulation related to fuel
economy standards.” California’s proposed greenhouse-gas standards do not simply
“relate to” fuel economy; they are fuel-economy standards. Even so,
federal courts have upheld them against preemption challenges because California
describes them as emission standards instead.
When a state regulator or judge can evade a clear and explicit preemption
by simply relabeling the prohibited conduct, it’s hard to see why Congress would
bother to enact regulatory statutes in the first place. For this reason (among
others), federal statutes must be read to bar not just the directly prohibited
conduct but also attempts at evasion. Contrary to Justice Thomas’s view, that
anti-circumvention principle is not some modern judicial extravagance; an
anti-circumvention “rule against mischief” showed up in British law as soon as
there were parliamentary statutes. In American constitutional and statutory
interpretation, the rule is as old as M’Culloch v. Maryland (1819) and
Gibbons v. Ogden (1824). The Wyeth majority’s
implied-preemption analysis calls the principle in doubt; Justice Thomas’s
opinion would repeal it outright, under “originalist” pretenses.
Wyeth is a disaster because preemption litigation is highly
asymmetric. For business groups, wins mean incremental gains, while losses tend
to choke off once-plausible arguments and to embolden aggressive state
regulators and trial lawyers. Defense lawyers will continue to achieve some
victories (for example, under federal statutes that regulate products rather
than labels), but they know that the Wyeth opinions seriously undermine
many of their strongest arguments.
Next on deck for Wyeth-style treatment is the banking industry. Ever
since the enactment of the National Bank Act in 1864, the banking operations of
federally chartered institutions have been shielded against investigation and
prosecution by the states. Cuomo v. Clearing House, to be argued and
decided later this term, may well end that regime. In that event, federal
financial institutions stand to “benefit” from expert oversight and impartial
investigation by state attorneys general. In seamless cooperation with a dozen
sure-footed federal regulators and congressional subcommittees, the AGs will
contribute greatly to the coherent regulation of our financial system.
That bit of sarcasm points to the true source of the Supreme Court’s
anti-preemption doctrine–the justices’ incomprehension of the country’s
constitutional predicament. The Stevens and Thomas opinions in Wyeth
teem with encomia to “federalism” and the need to protect states against federal
overreach. The court, they say, should not favor Congress by implying
preemption. But the federalism analysis is a fantasy, and the protestations of
neutrality are false.
Federal usurpation? Never in our history have the states wielded comparable
power, and comparably destructive power, over the commerce of the United States.
What “federalism” has come to mean, evidently, is the states’ right to exploit
the same branch of interstate commerce 50 times over. That absurdity is but a
facet of a broader problem–the proliferation of fragmented, semi-autonomous,
faction-ridden agencies and entities, from multi-state attorney-general
“investigations” to local juries, all of which exercise public power without
coordination or effective control. Implied preemption is, or was, one of the
very few checks on that tendency.
The court’s evisceration of that check is not an act of judicial neutrality;
it is an abject surrender of constitutional responsibility. We are experiencing
a malignant form of institutional competition–a three-branch, 50-state race for
first prize in the gratuitous destruction of American business and industry.
After Wyeth, the Supreme Court is leading by a nose.
Michael S. Greve is the John G. Searle Scholar at AEI.
There are no comments available.
1150 17th Street, N.W. Washington, D.C. 20036
© 2015 American Enterprise Institute for Public Policy Research